Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity

Hepatology Research

Volumn 38, Issue 1, 2008, Pages 60-69

  Takeda, Atsuya ^a,b   Takahashi, Masahiko ^b   Kunieda, Etsuo ^b,c   Takeda, Toshiaki ^b   Sanuki, Naoko ^a   Koike, Yuji ^b,c   Atsukawa, Kazuhiro ^d   Ohashi, Toshio ^c   Saito, Hidetsugu ^c   Shigematsu, Naoyuki ^c   Kubo, Atsushi ^c  

^a Ofuna Chuo Hospital   (Japan)

^b TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d Hiratsuka City Hospital   (Japan)

Author keywords

Ablation therapy; Hepatocellular carcinoma; Liver damage; Stereotactic radiotherapy; Transarterial chemoembolization

Indexed keywords

IODINATED POPPYSEED OIL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY TUMOR; LIVER CELL CARCINOMA; MALE; NAUSEA; PATIENT SAFETY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SCORING SYSTEM; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR THROMBUS; TUMOR VOLUME;

EID: 36549063071     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00084.x     Document Type: Article

References (56)

1. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 1904; 127 (Suppl 1): S17-26.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Dyer Z, Peltekian K, van Zanten SV. Review article: The changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 1905; 22: 17-22.
4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-3.
5. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 1900; 31: 330-5.
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-1900 EASL conference. European Association for the Study of the Liver. J Hepatol 1901; 35: 421-30.
7. Ryder SD, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 1903; 52 (Suppl 3): Iii1-8.
8. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 1903; 362: 1907-17.
9. Balsells J, Charco R, Lazaro JL et al. Resection of hepatocellular carcinoma in patients with cirrhosis. Br J Surg 1996; 83: 758-61.
10. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
11. Shiina S, Yasuda H, Muto H et al. Percutaneous ethanol injection in the treatment of liver neoplasms. AJR Am J Roentgenol 1987; 149: 949-52.
12. Castells A, Bruix J, Bru C et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 1121-6.
13. Livraghi T, Bolondi L, Buscarini L et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: A retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995; 22: 522-6.
14. Lencioni R, Pinto F, Armillotta N et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: A European experience. Eur Radiol 1997; 7: 514-19.
15. Orlando A, D'Antoni A, Camma C et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: A validated prognostic model. Am J Gastroenterol 1900; 95: 2921-7.
16. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 1905; 129: 122-30.
17. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma
18. Zhou ZH, Liu LM, Chen WW et al. Combined therapy of transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 1906; (E-pub ahead of print).
19. Mornex F, Girard N, Beziat C et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies: Mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 1906; 66: 1152-8.
20. Kim TH, Kim DY, Park JW et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 1906; 29: 568-75.
21. Hashimoto T, Tokuuye K, Fukumitsu N et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1906; 65: 196-202.
22. Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 1905; 104: 794-801.
23. Chiba T, Tokuuye K, Matsuzaki Y et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 1905; 11: 3799-805.
24. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 200-8.
25. Lewin K, Millis RR. Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol 1973; 96: 21-6.
26. Fuss M, Salter BJ, Herman TS, Thomas CR Jr. External beam radiation therapy for hepatocellular carcinoma: Potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 1904; 127 (Suppl 1): S206-17.
27. Cheng SH, Lin YM, Chuang VP et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14: 1025-33.
28. Lawrence TS, Ten Haken RK, Kessler ML et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992; 23: 781-8.
29. Cheng JC, Wu JK, Huang CM et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: Dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 1902; 54: 156-62.
30. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34: 861-70.
31. Wulf J, Hadinger U, Oppitz U, Olshausen B, Flentje M. Stereotactic radiotherapy of extracranial targets: CT- simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 1900; 57: 225-36.
32. Herfarth KK, Debus J, Lohr F et al. Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J Clin Oncol 1901; 19: 164-70.
33. Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys 1901; 51: 666-70.
34. Nagata Y, Negoro Y, Aoki T et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 1902; 52: 1041-6.
35. Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 1904; 101: 1623-31.
36. Takeda A, Kunieda E, Shigematsu N et al. Small lung tumors: long-scan-time CT for planning of hypofractionated stereotactic radiation therapy -initial findings. Radiology 1905; 237: 295-300.
37. Miften M, Wiesmeyer M, Monthofer S, Krippner K. Implementation of FFT convolution and multigrid superposition models in the FOCUS RTP system. Phys Med Biol 1900; 45: 817-33.
38. Mulier S, Mulier P, Ni Y et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 1902; 89: 1206-22.
39. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study. Radiology 1903; 226: 441-51.
40. de Baere T, Risse O, Kuoch V et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 1903; 181: 695-700.
41. Curley SA, Marra P, Beaty K et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 1904; 239: 450-8.
42. Nicoli N, Casaril A, Hilal MA et al. A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. Am J Surg 1904; 188: 165-7.
43. Bonatti H, Bodner G, Obrist P, Bechter O, Wetscher G, Oefner D. Skin implant metastasis after percutaneous radio-frequency therapy of liver metastasis of a colorectal carcinoma. Am Surg 1903; 69: 763-5.
44. Liang SX, Zhu XD, Xu ZY et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 1906; 65: 426-34.
45. Cheng JC, Wu JK, Lee PC et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 1904; 60: 1502-9.
46. Li B, Yu J, Wang L et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol 1903; 26: E92-9.
47. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 1905; 62: 1371-8.
48. Herfarth KK, Hof H, Bahner ML et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 1903; 57: 444-51.
49. Cheng S, Huang A. Liver and hepatobiliary tract. In: Perez C, Brady L, Halperin E, Schmidt-Ullrich R eds. Principles and Practice of Radiation Oncology, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 1904; 1589-606.
50. Wu DH, Liu L, Chen LH. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 1904; 10: 2184-9.
51. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1902; 54: 150-5.
52. Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 1901; 177: 645-55.
53. Fuss M, Thomas CR Jr. Stereotactic body radiation therapy: An ablative treatment option for primary and secondary liver tumors. Ann Surg Oncol 1904; 11: 130-8.
54. Carr B, Flickinger J, Lotze M. Hepatobiliary cancers. In: DeVita VT, Hellman S, Rosenberg SA eds. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 1997; 1087-128.
55. Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 1902; 224: 47-54.
56. Cheng JC, Chuang VP, Cheng SH et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1900; 47: 435-42.